Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/11/20 → 9/1/22 |
Funding
- Genentech Inc: $29,527.00
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma
- Patel, Reema (PI)